XKH004
XKH004 is a humanized monoclonal antibody injection independently developed by Kanova Biopharma, targeting both-17A and IL-17F. It can bind to homodimers IL-17A-A and IL-17F-F, well as heterodimer IL-17A-F. Extensive research has shown that the high expression of IL-17A and IL-17F associates with the occurrence of various systemic and local chronic inflammatory diseases. Neutralizing the upregulated IL-17A/F in the body or blocking the signaling pathway by IL-17A/F has become a hot spot in the development of drugs for autoimmune and inflammatory diseases.
XKH004 inhibits downstream inflammatory signaling pathways by blocking the interaction of IL-17A and IL-17F with their receptor, and is used in treating autoimmune and inflammatory diseases such as moderate to severe plaque psoriasis and ankylosing spondylitis (AS).
XKH004 is a novel monoclonal antibody with a new amino acid sequence, which patent has been granted in five countries, and Kanova possesses intellectual property rights.
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com